EU AI Act Penalties Begin August 2026
Which pharma AI systems are classified High Risk and what your QA team must do now.
The EU AI Act is no longer a future obligation. High Risk AI enforcement begins August 2026 — and pharmaceutical AI sits squarely in the High Risk category.
Which Pharma AI Systems Are High Risk?
The EU AI Act Annex III explicitly classifies as High Risk: clinical decision support AI, diagnostic AI in medical devices, batch release algorithms, visual inspection systems and pharmacovigilance signal detection. For pharmaceutical organisations, this covers the majority of production and clinical AI systems.
The Penalty Schedule
For High Risk AI non-compliance: up to €30 million or 6% of global annual turnover — whichever is higher. For prohibited AI: up to €35 million or 7%. The European AI Office is actively building enforcement capacity ahead of the August 2026 deadline.
Three Framework Compliance
Pharma organisations now face three simultaneous AI compliance obligations: EU GMP Annex 22 (now in force), ISPE GAMP AI Guide 2025 (the validation standard), and EU AI Act (enforcement August 2026). A single integrated gap assessment can cover all three simultaneously — contact us to discuss your requirements.